Evidence map›Paper›PMID 41964701›Full record

ReviewNeurochemical research2026

Targeting Ferroptosis and Necroptosis to Treat Stroke.

Bautista-Perez Sandra Monserrat, Silva-Islas Carlos Alfredo, Sánchez-Thomas Rosina, Figueroa Alejandra, Barrera-Oviedo Diana, Maldonado Perla D

Erratum issuedAbstract readReview
In one paragraph

Review in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Nutrients · 2026
    Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Bautista-Perez Sandra Monserrat *Departamento de Farmacología, Facultad de Medicina, Universidad Nacional Autónoma de México, 04510, Mexico City, México.
Silva-Islas Carlos Alfredo *Laboratorio de Patología Vascular Cerebral, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, 14269, Mexico City, México.
Sánchez-Thomas RosinaDepartamento de Farmacología, Facultad de Medicina, Universidad Nacional Autónoma de México, 04510, Mexico City, México.
Figueroa AlejandraDepartamento de Farmacología, Facultad de Medicina, Universidad Nacional Autónoma de México, 04510, Mexico City, México.
Barrera-Oviedo DianaDepartamento de Farmacología, Facultad de Medicina, Universidad Nacional Autónoma de México, 04510, Mexico City, México. diana.barrera@facmed.unam.mx.
Maldonado Perla D *Departamento de Farmacología, Facultad de Medicina, Universidad Nacional Autónoma de México, 04510, Mexico City, México. pmaldonado@facmed.unam.mx.

Funding

Consejo Nacional de Humanidades, Ciencias y Tecnologías , México A1-S-21433
6 · The paper itself

Abstract

Ischemic stroke is a leading cause of death and long-term disability worldwide. It results from cerebral blood flow obstruction (ischemia) and, in some cases, the restoration of cerebral blood flow (reperfusion), triggering a cascade of pathophysiological events collectively known as the ischemic cascade and reperfusion injury, which leads to the activation of different regulated cell death types, and this review focuses on necroptosis and ferroptosis. Both pathways are closely linked to oxidative stress and contribute significantly to neuronal death and inflammation following ischemic stroke. Dysregulation of redox homeostasis, iron dyshomeostasis, glutathione depletion, and mitochondrial dysfunction are key events in neuronal damage. Understanding the interplay between oxidative stress and these pathways is crucial for developing effective neuroprotective therapies. This review highlights recent advances in understanding necroptosis and ferroptosis in ischemic stroke, proposing redox-targeted interventions as promising strategies to mitigate brain injury and improve outcomes in patients affected by this condition.

Indexed as

FerroptosisIschemic StrokeNecroptosisNeuroprotective AgentsHumansOxidative StressNeuroprotective AgentsFerroptosisIschemic strokeNecroptosisOxidative stress

Identifiers

PMID41964701
PMCPMC13070077

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.